Evidence map›Paper›PMID 40130249›Full record

ArticleFrontiers in medicine2025

Epidemiological and clinical characteristics of COVID-19 mortality: a retrospective study.

Yaohua Hu, You Lu, Jiagui Dong, Delin Xia, Jin Li, Hong Wang, Min Rao, Chenxing Wang, Wanning Tong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yaohua Hu *Department of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
You Lu *Department of Respiratory Medicine, Shanghai Tenth People's Hospital, Shanghai, China.
Jiagui DongDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Delin XiaDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Jin LiDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Hong WangDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Min RaoDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Chenxing WangDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.
Wanning TongDepartment of Respiratory and Critical Care Medicine, Naval Medical Center of People's Liberation Army, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The global impact of SARS-CoV-2 and its associated coronavirus disease (COVID-19) has necessitated urgent characterization of prognostic biomarkers. This study aimed to delineate the epidemiological and clinical predictors of mortality among hospitalized COVID-19 patients. Methods: A retrospective cohort study was conducted on 123 patients with laboratory-confirmed COVID-19 admitted to Huoshenshan Hospital (Wuhan, China) from 1 February 2020 to 30 April 2020. Kaplan-Meier curve and multivariate Cox regression were used to assess the independent factors with survival time. Statistical significance was set at a Results: The cohort exhibited a mortality rate of 49.6% (61/123), with the critical clinical type (HR = 7.970, Conclusion: We revealed the epidemiological and clinical features of different clinical types of SARS-CoV-2 as summarized in this paper. We found that critical type, leukocyte, and lymphocyte are risk factors that affect survival time, which could be an early and helpful marker to improve management of COVID-19 patients.

Indexed as

COVID-19d-dimerepidemiologyleukocyteSARS-CoV-2

Identifiers

PMID40130249
PMCPMC11930819

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.